Autres langues Cybin Inc.

Actions

CYBN

CA23256X1006

Temps réel estimé Cboe BZX Autres places de cotation 21:57:42 16/07/2024			Varia. 5j.	Varia. 1 janv.
0,311 ^USD	-4,28 %		+16,43 %	-24,80 %

26/06	Cybin Inc. publie ses résultats pour l'exercice clos le 31 mars 2024	CI
11/06	Cybin Inc. nomme Atul R. Mahableshwarkar au poste de vice-président senior du développement clinique	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cybin Inc. Stands Strong As A Remaining Force To Prove Benefits Of Psychedelic Therapeutics ($CYBN)	10/07
A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update	08/07
Cybin : Meeting and Record of Notice Form 6 K	05/07
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights	26/06
Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	26/06
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference	19/06
Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development	11/06
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development	11/06
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024	29/05
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase	14/05
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones	07/05
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones	06/05
Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	06/05
Cybin to Participate at the 27th Annual Milken Institute Global Conference	25/04
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry	18/04
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	17/04
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	16/04
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder	16/04
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	10/04
Cybin : MATERIAL CHANGE REPORT - Form 6-K	22/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cybin Inc.

Actions

CYBN

CA23256X1006

Autres langues

Filtres